Atomo Revenue Jumps as HIV and Syphilis Tests Advance
AT1: $0.015 -6.25% · MC: $11M
Atomo Diagnostics reported first-quarter revenue of approximately $2 million, up 140% year on year, with HIV sales rising 38% and FebriDx and other OEM revenue increasing sharply from a lower base. The company also signed an agreement to develop a fourth-generation HIV test with Innovation Scientific, while its Active Syphilis test has transferred to manufacturing ahead of planned clinical trials. Atomo ended the quarter debt-free with approximately $3 million in cash; the HIV test launch and regulatory approvals remain planned, not secured.

Comments